The Annual World Drug Manufacturing Summit sources and presents leading global case studies from Pfizer, GSK, AstraZeneca, Baxter, Bayer and many more.
11th Annual World Drug Manufacturing Summit
26-28th November 2012
Venue: Swissôtel, Düsseldorf, Germany
www.wdmsummit.com
The Annual World Drug Manufacturing Summit sources and presents leading global case studies from Pfizer, GSK, AstraZeneca, Baxter, Bayer and many more.
The Summit is packed full of real life pharma manufacturing case studies, allowing you to benchmark your business against ‘best in class’ and ensure that you have the tools you need to form a coherent and logical strategy.
Key issues include:
If you have any questions about the new programme, would like to register your interest in speaking at WDM 2012, or would like to book your place please contact Richard Jones on +44 (0)20 7202 7690 or at Richard.jones@wtgevents.com. Please visit www.wdmsummit.com or to book now for the discounted price of £1,495 (usual price £1995 - £500 saving) visit www.wdmsummit.com/summer.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.